Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 25, 2020November 25, 2020

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

News

AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, ... Read more

June 29, 2020June 29, 2020

Investigational Agitation Treatment AXS-05 Named FDA Breakthrough Therapy

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Axsome Therapeutics‘ AXS-05, an investigational oral therapy for the treatment of agitation in people with Alzheimer’s ... Read more

June 1, 2020June 1, 2020

FDA Approves Tauvid as First Tau Protein Tracer Tool for Alzheimer’s Diagnosis

News

The U.S. Food and Drug Administration (FDA) has approved Tauvid (flortaucipir F18) as an imaging radiotracer agent — a radioactive diagnostic tool — to efficiently detect clumps of tau protein ... Read more

April 3, 2020April 3, 2020

Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments

News

Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance ... Read more

March 23, 2020March 23, 2020

Moderate Drinking Linked to Lower Amyloid-Beta Levels, Study Says

News

Moderate lifetime alcohol intake in middle-aged and older people who don’t show signs of dementia is associated with lower deposits of amyloid-beta, the protein that forms toxic aggregates in ... Read more

February 24, 2020February 24, 2020

Phase 2 Trial into Potential Oral Alzheimer’s Treatment Safe to Continue, Independent Board Says

News

A Phase 2 clinical trial testing Annovis Bio‘s oral therapy ANV401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review ... Read more

February 10, 2020February 10, 2020

NIH Awards $4.8M Grant to Project Investigating the Role of ApoE4 Gene Variant in Alzheimer’s

News

The National Institutes of Health (NIH) has awarded a $4.8-million grant to support a project designed to discover how the ApoE4 gene variant, a known genetic risk factor for ... Read more

January 29, 2020January 29, 2020

FDA to Review Adlarity as Skin Patch Treatment for Alzheimer’s Dementia

News

The U.S. Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for Adlarity — Corium’s once-weekly transdermal (skin) patch delivering donepezil — to treat ... Read more

January 22, 2020January 22, 2020

Levels of Circular RNAs in the Brains of Alzheimer’s Patients Linked to Disease Severity, Study Suggests

News

The levels of circular RNAs in the brains of patients with Alzheimer’s disease are linked to several traits and clinical measures of disease severity, a study shows. Because these circular ... Read more

January 21, 2020January 21, 2020

Scientists Identify Compounds That Can Protect Brain Mitochondria From Damage Associated With Alzheimer’s

News

A new screening assay has identified small molecules capable of protecting brain mitochondria from stress conditions that commonly occur in Alzheimer’s and other neurodegenerative diseases. These preclinical results in ... Read more